Catégories
Tout le CNR-MyRMA

Publications du CNR en 2024

Aliberti, S., Blasi, F., Burgel, P.-R., Calcagno, A., Fløe, A., Grogono, D., Papavasileiou, A., Polverino, E., Prados, C., Rohde, G., Salzer, H. J. F., Sánchez-Montalvá, A., Shteinberg, M., Van Braeckel, E., Van Ingen, J., Veziris, N., Wagner, D. and Loebinger, M. R. (2024). Mycobacterium avium complex pulmonary disease patients with limited treatment options. ERJ Open Res 10, 00610–02023, http://doi.org/10.1183/23120541.00610-2023.
Bémer, P., Aubry, A., Schramm, F., Koebel, C., Revillet, H., Baltes, V., Brun, C. L., Chazerain, P., Zeller, V., Hamdad, F., Morand, P. C., Guillouzouic, A., Piau, C., Roux, A.-L., Soueges, S., Martin, C., Gaudart, A., Hüssler, S., Fihman, V., Carricajo, A., Caruba, C. G., Bador, J., Dauchy, F.-A., Dutronc, H., Vignals, C. and Peuchant, O. (2024). Clinical features and treatment outcomes of bone and joint nontuberculous mycobacterial infections according to immune status: a 9-year retrospective observational cohort. International Journal of Infectious Diseases 146, 107122, http://doi.org/10.1016/j.ijid.2024.107122.
Bes-Berlandier, H., Garzaro, M., Rouzaud, C., Bodard, S., Bille, E., Ficheux, M., Cazals-Hatem, D., Veziris, N., Lanternier, F. and Lortholary, O. (2024). Successful rescue TNF-α blocking for Mycobacterium genavense – Related immune reconstitution inflammatory syndrome: A case report. Heliyon 10, e29341, http://doi.org/10.1016/j.heliyon.2024.e29341.
Cambau, E., Delogu, G., Van Ingen, J., Herrmann, J.-L. and Winthrop, K. (2024). All you want to know about Mycobacterium abscessus. Clinical Microbiology and Infection S1198743X24000946, http://doi.org/10.1016/j.cmi.2024.02.019.
Friesen, I., Saluzzo, F., Groenheit, R., Aubry, A., Anthony, R., Niemann, S., Mathys, V., Cirillo, D. M., Indra, A., Mathys, V., Atanasova, Y., Obrovac, M., Žmak, L., Pieridou, D., Dvořákov, V., Troels Lillebæk, Kummik, T., Klaos, K., Soini, H., Haanperä-Heikkinen, M., Mentula, S., Jérôme, R., Cambau, E., Niemann, S., Panayotis, I., Papaventsis, D., Bakos, Á., Szél, V., Lőrinczi, L. K., Fitzgibbon, M., Boyle, B., Cirillo, D. M., Giannoni, F., Pole, I., Norvaiša, I., Vasiliauskaite, L., Perrin, M., Deguara, C., Anthony, R., Mengshoel, A. T., Augustynowicz-Kopeć, E., Macedo, R., Coriu, R. M., Porvaznik, I., Klemen, Š., Herrera-León, L., Groenheit, R. and Werngren, J. (2024). Re: “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe” by Lange et al. Clinical Microbiology and Infection S1198743X24002775, http://doi.org/10.1016/j.cmi.2024.06.001.
Godefroy, N., Monsel, G., Jauréguiberry, S., Henry, B., Véziris, N., Aubry, A., Robert, J., Jachym, M., Caumes, E. and Pourcher, V. (2024). Lessons learned from treating drug-resistant TB and how to apply these to drug-susceptible TB. int j tuberc lung dis 28, 357–359, http://doi.org/10.5588/ijtld.23.0548.
Godmer, A., Bigey, L., Giai‐Gianetto, Q., Pierrat, G., Mohammad, N., Mougari, F., Piarroux, R., Veziris, N. and Aubry, A. (2024). Contribution of machine learning for subspecies identification from Mycobacterium abscessus with MALDI‐TOF MS in solid and liquid media. Microbial Biotechnology 17, e14545, http://doi.org/10.1111/1751-7915.14545.
Hasker, E., Assoumani, Y., Randrianantoandro, A., Ramboarina, S., Braet, S. M., Cauchoix, B., Baco, A., Mzembaba, A., Salim, Z., Amidy, M., Grillone, S., Attoumani, N., Grillone, S. H., Ronse, M., Peeters Grietens, K., Rakoto-Andrianarivelo, M., Harinjatovo, H., Supply, P., Snijders, R., Hoof, C., Tsoumanis, A., Suffys, P., Rasamoelina, T., Corstjens, P., Ortuno-Gutierrez, N., Geluk, A., Cambau, E. and De Jong, B. C. (2024). Post-exposure prophylaxis in leprosy (PEOPLE): a cluster randomised trial. The Lancet Global Health 12, e1017–e1026, http://doi.org/10.1016/S2214-109X(24)00062-7.
Kassegne, L., Veziris, N. and Fraisse, P. (2024). Analyse pharmacologique du traitement des pneumopathies à Mycobacterium abscessus. Revue des Maladies Respiratoires 41, 29–42, http://doi.org/10.1016/j.rmr.2023.10.010.
Lange, C., Kherabi, Y., Guglielmetti, L., Duarte, R. and Günther, G. (2024). Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author’s response. Clinical Microbiology and Infection 30, 1207–1208, http://doi.org/10.1016/j.cmi.2024.06.009.
Loebinger, M. R., Aliberti, S., Haworth, C., Jankovic Makek, M., Lange, C., Lorent, N., Papavasileiou, A., Polverino, E., Rohde, G., Veziris, N., Wagner, D. and Van Ingen, J. (2024). Patients at risk of nontuberculous mycobacterial pulmonary disease who need testing evaluated using a modified Delphi process by European experts. ERJ Open Res 10, 00791–02023, http://doi.org/10.1183/23120541.00791-2023.
Maitre, T., Baulard, A., Aubry, A. and Veziris, N. (2024). Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis. Infectious Diseases Now 54, 104807, http://doi.org/10.1016/j.idnow.2023.104807.
Maitre, T., Guglielmetti, L., Robert, J., Aubry, A. and Veziris, N. (2024). Avancées dans l’antibiothérapie de la tuberculose. Rev Prat 74, 239–244.
Maitre, T., Godmer, A., Mory, C., Chauffour, A., Mai, T. C., El Helali, N., Aubry, A. and Veziris, N. (2024). Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis Ed. Wasserman, S. Antimicrob Agents Chemother e00583-24, http://doi.org/10.1128/aac.00583-24.
Mengeot, L., Jachiet, M., Bourrat, E., Mahé, A., Cambau, E., Bernard, E., Pasqualini, C., Chamouine, A., Truong, J., Dumaine, C., Bertolotti, A. and Franco, J. (2024). Effective management of severe chronic erythema nodosum leprosum in adolescent patient using ustekinumab and apremilast: A case report. Acad Dermatol Venereol 38, http://doi.org/10.1111/jdv.19552.
Rupasinghe, P., Ashraf, A., Barreda, N., Parveen, S., Zubair, M., Calderon, R., Asif, S., Hirani, N., Chingisova, L., Bulane, A., Hang, P. T., Ha, D. T., Ardizzoni, E., Kursheed, N., De Rijk, W. B., Rigouts, L., Guglielmetti, L., Mitnick, C. and De Jong, B. C. (2024). Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin Ed. Wasserman, S. Antimicrob Agents Chemother 68, e01701-23, http://doi.org/10.1128/aac.01701-23.
Tagliani, E., Kohl, T. A., Ghodousi, A., Groenheit, R., Holicka, Y., Niemann, S., Maurer, F. P., Cirillo, D. M. and Cambau, E. (2024). Appeal from the European tuberculosis reference laboratory network (ERLTB-Net) for improving the diagnosis of infections due to nontuberculous mycobacteria. Clinical Microbiology and Infection 30, 4–6, http://doi.org/10.1016/j.cmi.2023.06.005.
Veziris, N., Aubry, A., Bonnet, I., Petersen, T., Poignon, C., Gydé, E., Guglielmetti, L. and Robert, J. (2024). Actualités sur la tuberculose à bacilles multirésistants aux antibiotiques et ses nouveaux traitements. Bull Épid Hebdo 127–131, URL: http://beh.santepubliquefrance.fr/beh/2024/6-7/2024_6-7_4.html [Accessed March 2024].